The Innovation in Respiratory Infections and Tuberculosis Diagnosis Group, also known with its acronym One and a Half Group, is located at Germans Trias i Pujol Research Institute (IGTP), Germans Trias i Pujol University Hospital (HUGTiP) and the Genetics and Microbiology Department in the Biosciences Faculty of Universitat Autònoma de Barcelona (UAB). The group is are affiliated with the CIBERES network (CB06/06/0031) and recognised by the Catalan Government as a consolidated research group (2017SGR-0492 and 2021SGR-1267). Thanks to this recognition, the group has cemented its activity and future perspectives. Currently, the team has matured scientifically, developing solid and productive independent research lines. The consolidation of these research lines is a result of their commitment to integrating clinical and translational research into their activities.

In recent years, the research group has seen the emergence of two new principal investigators who are now leading their own research teams. Dr Irene Latorre, a recipient of the Miguel Servet Program, leads a group focused on characterising the immune response in tuberculosis and SARS-CoV-2 infections. Dr Alícia Lacoma, a CIBER researcher affiliated with IGTP, leads a group studying microbial interaction and the impact of environmental factors on infections.

The group closely collaborates with the following clinical researchers from HUGTiP: Dr Lourdes Mateo (Rheumatology Department), Dr Fernando Armestar (Intensive Care Unit), Dr Irma Casas and Dr Júlia Valera (MD, PhD student) from the Preventive Medicine Department, Dr Maria Méndez and Dr Clara Carreras from the Paediatric Department, and Dr Zoran Stojanovic (MD, PhD student) and Dr Filipe Carvalho (MD, PhD Student) from the Pulmonology Department.

Several members of the SGR Group are based outside the Can Ruti Campus: at the Tuberculosis Unit Vall d'Hebron-Drassanes of Hospital Universitari Vall d'Hebron (Dr Maria Luiza de Souza and Dr M. Angeles Jiménez), at Serveis Clínics (Dr Joan Pau Millet and Dr Xavier Casas), and at the Pulmonology Department of Hospital Moises Broggi (Dr Fina Sabria and Dr Lydia Luque).

The group is leading two European networks, INNOVA4TB and ADVANCE-TB, both funded by the European Commission and involving partners from over 50 countries.

Keywords: Diagnostic, host immune response, microbial interaction, environmental factors, antimicrobial therapies.

Group leader

  • José Domínguez Benítez
    José Domínguez Benítez

    José Domínguez Benítez

    Dr José Domínguez studied Biological Sciences at the University of Barcelona, Spain. He completed the Master's Degree in Applied Microbiology and also received a PhD in Microbiology from Universitat Autònoma de Barcelona (UAB), Spain. Domínguez is an assistant professor at the Department of Genetics and Microbiology of UAB where he teaches undergraduate and postgraduate studies.

    Contact: jadominguez(ELIMINAR)@igtp.cat

Research lines

The group is working in the field of the respiratory infections and tuberculosis, improving the understanding of the host-pathogen-external factors interaction, and exploring new approaches both for diagnosis and treatment.

Scientific challenges and strategic objectives for the next 3 years are described below for each research line.

Microbial interactions

The group’s research explores the microbial mechanisms of adaptation to the respiratory tract and aspects related to clinical presentation together with specific phenotypic and genotypic traits of microorganisms by using novel bioinformatic and genomic approaches. Research is mostly focused on Staphylococcus aureus and Mycobacterium tuberculosis, but Pseudomonas aeruginosa, Streptococcus pneumoniae and Haemophilus influenzae have been also studied for aspects such as carrier status versus colonisation versus infection in the respiratory tract. The objective is to identify differential factors that will allow the design of diagnostic tools to distinguish colonisation from infection, in order to optimise treatment, to design novel targets as well as improve drug delivery systems that will contribute to treatment success and to reduce the emergence of antimicrobial resistance in lower respiratory tract infections.

Immune response characterisation

The group studies the diagnostic and prognostic importance of inflammation markers in different infectious diseases and clinical syndromes, in collaboration with several hospital departments. The team is studying the host immune response to different antigens specific of M. tuberculosis, in both animal models and in humans, and also at peripheral and local level, to characterise the different stages of the TB spectrum. The group has experience in the study of the immune response by conventional and spectral flow cytometry, performing deep immune profiling, as well as studies on the characterisation of different cellular subsets. SARS-CoV-2 immune response has also been characterized in different groups of patients. Finally, the interaction between neutrophils and S.aureus has also been explored, including the formation of NETs after specific stimulation.

Impact of external factors

The group has consolidated the 2D in vitro model of intracellular persistence in murine/human alveolar macrophages, which allows them to carry out trials to explore the impact of environmental pollutants: tobacco smoke, e-vapor of e-cigarette, diesel exhaust particles, and micro and nanoplastics, in the persistence of M.tuberculosis and also S.aureus. They have also studied the impact of pollutants in the immune response against bacteria, and how the bacteria modify its phenotype for adapting to the toxic environment produced by the tobacco.

Diagnostic technology innovation

The team is using molecular, metabolomics and immunological techniques to develop innovative diagnostic technologies. They are also developing and evaluating new molecular methods for studying mutations associated with resistance to anti-TB drugs. In the last years, the group has patented three technologies related with the diagnosis of the mycobacterial infections, and licensed two of them.

New therapeutic approaches

The group is conducting studies involving the search and refinement of anti-infective drugs, but also the use of novel drug delivery systems loaded with conventional S. aureus and M. tuberculosis drugs. Conventional in vitro susceptibility studies are performed; and nanoparticles efficacy are also tested in infection cell models. These nanoparticles are produced by the group led by Dr Manuel Arruebo (Universidad de Zaragoza, Spain) in the framework of CIBERES and CIBER-BBN collaboration.

Active projects

Innovation for TB. INNOVA4TB

PI: J. Domínguez
Funding agency: H2020-MSCA-RISE-2018
Agency code: 823854
Duration: 2019 - 2024

Tuberculosis: Development of new diagnostic methods, new host-direct therapies and understanding the impact of extrinsic factors in modulating inflammation (INNOVA2)

PI: J.Domínguez
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: PI19/01408
Duration: 2020 – 2024

Pneumococcal pNeumonia Epidemiology, Urine serotyping, and Mental Outcomes. The PnEUmo Study in Europe (PNEUMO)

Central PI: M. Bonten; Scientific Coordinator C. Prat Aymerich
PIs at HUGTiP: A. Lacoma and F. Armestar
Funding agency: University Medical Center Utrecht
Agency code: 820755
Duration: 2020 - 2026 (until 2024 in Spain)

Multi-centre EuRopean study of MAjor Infectious Disease Syndromes (MERMAIDS) - Acute Respiratory Infections (MERMAIDS ARI) 2.0

Part of the Consortium Rapid European COVID19 Research Response (RECOVER).
Consortium coordinator: Herman Goossens
Sponsor Europe: UMC Utrecht; PI: Patricia Bruijning
Coordinating investigator: C. Prat-Aymerich
PI at HUGTiP: Zoran Stojanovic
Funding agency: European Union's Horizon 2020 research and innovation programme
Agency code: ClinicalTrials.gov identifier NCT04364711, grant agreement No 101003589

ChildTB-Omics: Omics for diagnosis of tuberculosis in children and adolescents

PI: Begoña Santiago
Financing agency: Fondo de Investigaciones Sanitarias – Instituto de Salud Carlos III (ISCIII)
Grant reference: PI20/01607
Duration: 2021 - 2024

Innovative tools to study the impact and mode of action of micro and nanoplastics on human health: towards a knowledge base for risk assessment (PLASTICHEAL)

PI: Ricard Marcos
Financing agency: H2020-SC1-2020-Single-Stage-RTD. Agency code: 965196
Duration: 2021 - 2024

Towards an improvement in diagnostics and treatment strategies for TB control. (ADVANCE-TB)

PI: Alicia Lacoma
Grant Holder Scientific Coordinator: José Domínguez
Grant Awarding Coordinator: Cristina Prat-Aymerich
Funding entity: COST Action. Horizon 2020.
Agency code: CA21164
Duration: 2022 - 2026

Hacia una mejora en las estrategias de diagnóstico y tratamiento y una mejor comprensión del impacto de los factores extrínsecos para el control de la tuberculosis. ADVANCE-TB

PI: J. Domínguez
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: PI22/01834
Duration: 2023 - 2026

Caracterización de la respuesta inmune en el manejo de la infección por SARS-CoV-2

PI: Irene Latorre
Funding agency: Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)
Duration: 2021 - 2024

Deep immune profiling of Mycobacterium tuberculosis local and systemic cell response - TB-IMMUN

PI: Irene Latorre
Financing entity: Instituto de Salud Carlos III (ISCIII)
Agency code: PI21/00724
Duration: 2021 - 2024

Unraveling host systemic and tissue-specific Mycobacterium tuberculosis immunity for a better control of the disease

PI: Irene Latorre
Funding agency: Subdirección General de Evaluación y Fomento de la Investigación
Agency code: CP20/00070
Duration: 2021 - 2024

A Phase 2, Comparative Randomised Trial to Evaluate the impact of reduced COVID-19 mRNA vaccination regimens on immunological responses and reactogenicity in paediatric subjects with and without prior SARS-CoV-2 infection (CoVacc)

Part of the European Clinical Research Network for the coordination and condult of COVID-19 vaccine trials (VACCELERATE)
Central PI: Patricia Bruijning-Verhagen; Role C.Prat: Lead Medical Monitor
Funding entity: European Union H2020-IBA-SC1-CORONAVIRUS-2020-4
Agency code: Grant agreement number 101037867
Sponsor: UMC Utrecht (Netherlands)

ADEQUATE Advanced Diagnostics for Enhanced QUality of Antibiotic prescription in respiratory Tract infections in Emergency rooms

Consortium VALUE Dx, the value of diagnostics. Coordinator. Herman Goossens
PIs: CPrat, Julia Bielicki. WP4b co-leaders
Funding agency: Innovative Medicines Initiative 2 Joint Undertaking
This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited
Agency code: Grant agreement No 820755.
Sponsor: UMC Utrecht (Netherlands). Currently in process of
sponsorship transfer to Penta Network

Preparedness of the health care system in Ukraine to control TB during and after the war

PI: Andrii Dudnyk
Funding agency: Marie Skłodowska Curie Action for Ukraine (EU-Horizon Europe). Alexander von Humboldt Foundation
Agency code: 1233336
Duration: 2023 - 2025

Facing tuberculosis through urinary biomarkers

PI: J. Domínguez
Funding agency: AGAUR
Agency code: PRODUCTE-0050
Duration: 2023 - 2024

Past projects

Evaluar la utilidad de una nueva técnica en el diagnóstico de las infecciones por micobacterias no tuberculoses Ref. 18/691

PI: J. Domínguez
Funding agency: Sociedad Española de Neumología y Cirugía Torácica
Duration: 2019 – 2023

BCG vaccination to Reduce the impact of COVID-19 in healthcare workers following Coronavirus Exposure (BRACE) Trial

Chief PI: Nigel Curtis, Murdoch's Children Research Institute Melbourne Australia
PI in Europe: Marc Bonten; Role C.Prat-Aymerich: coordinating investigator (Netherlands and Spain)
PI at HUGTiP: Antoni Rosell Gratacós
Funding agency: Bill and Melinda Gates
Agency code: HREC/protocol no: 62586 NCT04327206. EUDRACT 2020-002503-19
Sponsor in Europe: UMC Utrecht 

Point-of-care tests for the rapid detection of SARS-CoV-2 (POC4CoV)

PI: Maria Pilar Marcos
Financing agency: Fondo COVID-19 - Instituto de Salud Carlos III 8ISCIII)
Agency code: 202050E090
Duration: 2020 - 2021

A multinational, phase 2, randomized, adaptative protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines administration in older adults (>75) already vaccinated against SARS-CoV-2 (EU-COVAT-1_AGED)

Part of the European Clinical Research Network for the coordination and condult of COVID-19 vaccine trials (VACCELERATE)
Coordinator: Prof Oliver A. Cornely
PI at HUGTiP: José Moltó; Laboratory lead: José Domínguez
Funding agency: Horizon 2020
Agency code: Agreement number 101037867. EudraCT nº. 2021-004526-29
Sponsor: University of Cologne (Germany)

Scientific publications

Highlighted publications

Wheatley RM, Caballero JD, van der Schalk TE, De Winter FHR, Shaw LP, Kapel N, Recanatini C, Timbermont L, Kluytmans J, Esser M, Lacoma A, Prat-Aymerich C, Oliver A, Kumar-Singh S, Malhotra-Kumar S, Craig MacLean R. Gut to lung translocation and antibiotic mediated selection shape the dynamics of Pseudomonas aeruginosa in an ICU patient. Nat Commun. 2022 Nov 22;13(1):6523. DOI: 10.1038/s41467-022-34101-2.

Domínguez J, Boeree MJ, Cambau E, Chesov D, Conradie F, Cox V, Dheda K, Dudnyk A, Farhat MR, Gagneux S, Grobusch MP, Gröschel MI, Guglielmetti L, Kontsevaya I, Lange B, van Leth F, Lienhardt C, Mandalakas AM, Maurer FP, Merker M, Miotto P, Molina-Moya B, Morel F, Niemann S, Veziris N, Whitelaw A, Horsburgh CR Jr, Lange C; TBnet and RESIST-TB networks. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. Lancet Infect Dis. 2023 Apr;23(4):e122-e137. DOI: 10.1016/S1473-3099(22)00875-1.

Hamada Y, Gupta RK, Quartagno M, Izzard A, Acuna-Villaorduna C, Altet N, Diel R, Dominguez J, Floyd S, Gupta A, Huerga H, Jones-López EC, Kinikar A, Lange C, van Leth F, Liu Q, Lu W, Lu P, Rueda IL, Martinez L, Mbandi SK, Muñoz L, Padilla ES, Paradkar M, Scriba T, Sester M, Shanaube K, Sharma SK, Sloot R, Sotgiu G, Thiruvengadam K, Vashishtha R, Abubakar I, Rangaka MX. Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis. EClinicalMedicine. 2023 Jan 5;56:101815. DOI: 10.1016/j.eclinm.2022.101815.

Pittet LF, Messina NL, Orsini F, Moore CL, Abruzzo V, Barry S, Bonnici R, Bonten M, Campbell J, Croda J, Dalcolmo M, Gardiner K, Gell G, Germano S, Gomes-Silva A, Goodall C, Gwee A, Jamieson T, Jardim B, Kollmann TR, Lacerda MVG, Lee KJ, Lucas M, Lynn DJ, Manning L, Marshall HS, McDonald E, Munns CF, Nicholson S, O'Connell A, de Oliveira RD, Perlen S, Perrett KP, Prat-Aymerich C, Richmond PC, Rodriguez-Baño J, Dos Santos G, da Silva PV, Teo JW, Villanueva P, Warris A, Wood NJ, Davidson A, Curtis N; BRACE Trial Consortium Group. Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers. N Engl J Med. 2023 Apr 27;388(17):1582-1596. DOI: 10.1056/NEJMoa2212616.

Villar-Hernández R, Latorre I, Noguera-Julian A, Martínez-Planas A, Minguell L, Vallmanya T, Méndez M, Soriano-Arandes A, Baquero-Artigao F, Rodríguez-Molino P, Guillén-Martín S, Toro-Rueda C, De Souza-Galvão ML, Jiménez-Fuentes MÁ, Stojanovic Z, Sabriá J, Santos JR, Puig J, Domínguez-Álvarez M, Millet JP, Altet N, Galea Y, Muriel-Moreno B, García-García E, Bach-Griera M, Prat-Aymerich C, Julián E, Torrelles JB, Rodrigo C, Domínguez J. Development and Evaluation of an NTM-IGRA to Guide Pediatric Lymphadenitis Diagnosis. Pediatr Infect Dis J. 2024 Mar 1;43(3):278-285. DOI: 10.1097/INF.0000000000004211.


Additional information

Collaborative networks

  • CIBER Respiratory Diseases (CIBERES) Group 17 (CB06/0031), from 2007.
  • Tuberculosis Network European Trials group (TBnet), from 2012.
  • Unidad Asistencial de Excelencia en Tuberculosis, accredited by the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), from 2015.
  • Spanish network MYCONET, accredited by Ministerio de Economia, Industria y Competitividad, from 2017.
  • Study Group for Staphylococci and Staphylococcal Diseases. European Society of Clinical Microbiology and Infectious Diseases, from 2018.
  • COMBACTE CLIN-Net. COMBACTE's clinical hospital network was built within COMBACTE-NET, COMBACTE-CARE and COMBACTE-MAGNET, all IMI-funded projects within the New Drugs for Bad Bugs program, dedicated to combat antimicrobial resistance through collaborative research since 2013. In October 2023, COMBACTE will conclude its ten-year mandate: building a sustainable clinical research network. Since 1 June 2022, CLIN-Net was sustained in the European Clinical Research Alliance on Infectious Diseases - ECRAID. That means that the network built over the last decade will continue as part of the not-for-profit ECRAID network.

Doctoral theses

Title: Pooling samples to increase testing capacity for Tuberculosis and COVID-19 diagnosis
Author: Vibol Iem (Laos)
Supervisors: International PhD Supervision
Primary supervisors: Tom Wingfield, Luis E. Cuevas
Secondary supervisors: Jose Dominguez, Jahangir Khan
Institution: Liverpool School of Tropical Medicine (UK)
Academic year of defence: 2022-2023

Title: Assessing the incidence of COVID-19 infection among the frontline healthcare workers in the federal capital territory, Abuja, Nigeria
Author: Saddiq T. Abdurrhaman (Nigeria)
Supervisor: J. Domínguez
University: Universitat Autònoma de Barcelona (UAB)
Academic year of defence: 2022-2023


Additional noteworthy activities of the research group that are worth mentioning relate to dissemination, social impact, research transference, and excellence indicators.

Regarding dissemination, it is important to note that all the activities of the research group are posted on IGTP’s website, and the X, Instagram, Facebook, and LinkedIn accounts of the group (@Oneandahalf_Lab; @innova4tb). The social network accounts allow for a dissemination of their research results and scientific activities to society in a fast and accessible way.

Actions that will have social impact are a priority for the research group. As previously explained, the team leads INNOVA4TB, an H2020 RISE consortium, where three partners are from Ukraine and one from Moldova. They have also applied to a COST application (ADVANCE-TB consortium) where partners from Ukraine, Moldova, Georgia, Armenia, North Macedonia, Romania, and even Nigeria are involved. One of the main objectives of these consortiums is to favour the exchanges of staff between institutions, in order to improve their professional careers. This action has a clear social impact, as it improves the quality of the research in all the country partners, enhances TB control, and assists young scientists and physicians in their career development, especially in Eastern countries and particularly in these threatening times.

The team exhibits a pro-active tech transfer behaviour. The group holds three patents in national phases. Two of them are licensed, and the third is in negotiations with an IVD Company. In all cases, the group has been invited to participate in the co-development of the final product. In one case, a member of the group was employed for a full year in the R+D department of the company, and will now be hired to be in charge of the final steps of the market release.

Finally, as an indicator of excellent research, it is noteworthy that the papers published by the group have reached more than 1000 citations.

Public engagement in research and innovation. The group is establishing participatory multi-actor dialogues between researchers, policy makers, industry, and civil society organizations, NGOs, and citizens to define the scientific research priorities.

In 2021, the group organised, with the collaboration of TB-REP 2.0, a symposium for discussing the role of civil society in TB diagnostics and management. TB-REP 2.0 is a multi-country program covering 11 countries in the Eastern Europe region. Representatives of more than 25 small and medium NGOs from Eastern Europe and Euro-Asia countries participated in the event. During the symposium, the need for non-invasive methods that provide rapid results was emphasized as key to reducing the burden of the disease, reducing the stigma that patients suffer, and increasing the well-being of the citizens and the society.

The group also participated in 2021 in an international online course about “Community Engagement in TB Research & Development: Looking for Innovations”, oriented to civil society that was also organized in collaboration with TB-REP 2.0. The group discussed with representatives of the civil society about the preventive therapy of tuberculosis, and the needs of diagnostics and vaccines. These actions contribute to building a more scientifically literate society able to actively participate in and support democratic processes, and science and technology developments. The group plans to continue in contact with the NGOs for involving them in the research strategies of the group. It is also planned to continue with outreach activities. Continuous information will be released from the group through social networks (X, LinkedIn, Instagram, and Facebook), and conventional media (Newspaper, radio, and TV).

Enabling easier access to scientific results. The group prioritises the publication of results in open access formats, improving the dissemination of their research. Additionally, the group has established a Research Data Management Plan (DMP). They commit to follow guidelines outlined by the EC, Science Europe, and national requirements. Handling of research data and the objects on which the data is based is carefully planned, documented, and described, which will allow the integrity and reproducibility of scientific results. The Data Management follows the FAIR data principles. The group supports the development and consolidation of the European Open Science Cloud (EOSC) as a web of FAIR data. Data generated is available under the CC BY or CC 0 license. Following current legislation [Regulation (EU) 2016/679 of Parliament European Council and of the Council of April 27, 2016 on Data Protection (RGPD)], all clinical data is treated confidentially. The access to the data is granted only for research purposes. The data is stored in a REDCap (Research Electronic Data Capture) database, deposited in IGTP servers. REDCap is a secure web application for building and managing online surveys and databases.

Take up of gender in R&D content and process. The research group has created an environment that promotes responsible conduct and fosters integrity by individual researchers. Gender policies are established and will continuously monitor structures, processes, and procedures, which would: a) Give equal skills to both men and women; b) Encourage respect for everyone, especially women, involved in the research environment; c) Promote productive interactions between all research staff irrespective of gender.

The constitution of the group is almost 50% men (9) and women (11). The gender balance in decision-making is assured, all leaders of the Experimental Research Teams are women; and 8 of the 12 researchers of the Clinical Research Team are also women. The gender issue is also considered in the research design and methodologies. Tuberculosis is affecting a large amount of the population, and the incidence in women is increasing, probably associated with other risk factors. Therefore, the group will make all efforts to address this issue.

However, the group will go one step further. It is going to constitute, in the framework of the INNOVA4TB consortium, the Equal Opportunities Commission (EOC) that will take care of gender balance, but also will work towards the elimination of discrimination on the grounds of marital status, pregnancy, breastfeeding, disability, family status, and race.

Take up of ethics in R&D content and process. Ethics is an integral part of research from the beginning to the end. Ethical research conduct implies the application of fundamental ethical principles and legislation to scientific research. The group will look after the avoidance of any breach of research integrity, which means, in particular, avoiding fabrication, falsification, plagiarism or other research misconduct.

The group has the ethics approval from the different Ethics Committee institutions participating in all their studies. The group complies with the local statutes and adheres to local ethical guidelines. The projects comply with the WMA Declaration of Helsinki (Fortaleza, 2013); the Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine (Oviedo, 4 April 1997) (Oviedo Bioethics Convention); the EU Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use as well as the requirements for authorization of the manufacturing or importation of such products (OJ L 91, 9.4.2005, p. 13), the EU Regulation No 536/2014 of the European Parliament and of the Council on clinical trials on medicinal products for human use, repealing Directive 2001/20/EC (OJ L 158, 27.5.2014). The group will also follow the recommendations of the European Textbook on Ethics in Research from the European Commission - EUR 24452 EN - 2010.

Formal and informal science education. Building capacities and developing innovative ways of connecting science to society is one of the priorities. This will help to make science more attractive to young people, increase society's appetite for innovation, and open up further research and innovation activities. In this sense, the group has planned the following actions: 1) Press releases to newspapers and feature articles in magazines. 2) Presentation of results and training actions in local TV and radio. 3) Release updated group information on the official webpage and social networks. 4) Specific actions in press, and open conferences on World TB Day (24 March). 5) High school conferences. 6) Participation in the "Open Researcher's Night" and "Science Open Day".

In 2021, the group participated in the project titled "European Performing Science Night (EPSN)" led by la Fundació Èpica La Fura dels Baus, granted by the H2020 program (H2020-MSCA-NIGHT-2020bis). This initiative aimed to bring researchers closer to the public and enhance their recognition, work, and the value they bring to society. To achieve these goals, the project incorporated various activities that blend science, art, and technology. Initially, EPSN organised a workshop for participating researchers, focusing on co-creation methodologies to foster synergies between different groups and disciplines, and to facilitate communication with the audience. Following this, a co-creation workshop specifically designed for scientists, technologists, and artists was held from 13 to 25 September. This workshop culminated in a public performance that interpreted the challenges and research topics discussed by the experts during the initial workshop. The outcomes of this workshop were then presented in a public session that featured exhibitions, interactive experiences, and talks, all aimed at promoting the values of science and demonstrating the impact and attractiveness of researchers' work to motivate young people to pursue research careers.


- Recerca, Conferències, Projectes,

El consorci internacional INNOVA4TB posa fi a cinc anys de recerca puntera en tuberculosi

El 21 de març va tenir lloc l'última trobada d'INNOVA4TB, un consorci liderat des de l'IGTP amb investigadors d'arreu del món. Els participants han presentat els resultats dels diferents paquets de treball i han valorat la feina feta des de l'any 2019. L'IGTP seguirà involucrat en altres xarxes com ADVANCE-TB i SMA-TB.

- Institucional

Celebrant el Dia Internacional de la Dona: la veu de les nostres professionals

Per commemorar el Dia Internacional de la Dona, hem realitzat quatre preguntes a investigadores de diversos perfils de l'IGTP i professionals de diverses àrees de suport a la recerca. L'objectiu és conèixer les dificultats amb què s'han enfrontat com a dones en el camp professional  i entendre les seves perspectives sobre el futur.

+ Notícies